BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 18375923)

  • 21. Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.
    Faggiano A; Grimaldi F; Pezzullo L; Chiofalo MG; Caracò C; Mozzillo N; Angeletti G; Santeusanio F; Lombardi G; Colao A; Avenia N; Ferolla P
    Endocr Relat Cancer; 2009 Mar; 16(1):225-31. PubMed ID: 19004986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
    Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
    Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
    [No Abstract]   [Full Text] [Related]  

  • 23. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.
    Treglia G; Cocciolillo F; Di Nardo F; Poscia A; de Waure C; Giordano A; Rufini V
    Acad Radiol; 2012 Oct; 19(10):1290-9. PubMed ID: 22819076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Localization of medullary thyroid carcinoma after surgery using (11)C-methionine PET/CT: comparison with (18)F-FDG PET/CT.
    Jang HW; Choi JY; Lee JI; Kim HK; Shin HW; Shin JH; Kim SW; Chung JH
    Endocr J; 2010; 57(12):1045-54. PubMed ID: 20978365
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Evaluation of efficacy and clinical impact of 18F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test].
    Gómez-Camarero P; Ortiz-de Tena A; Borrego-Dorado I; Vázquez-Albertino RJ; Navarro-González E; Ruiz-Franco-Baux JV; Cuenca-Cuenca JI
    Rev Esp Med Nucl Imagen Mol; 2012 Sep; 31(5):261-6. PubMed ID: 23067528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of In-111 octreotide and Tc-99m (V) DMSA scintigraphy in the detection of medullary thyroid tumor foci in patients with elevated levels of tumor markers after surgery.
    Arslan N; Ilgan S; Yuksel D; Serdengecti M; Bulakbasi N; Ugur O; Ozguven MA
    Clin Nucl Med; 2001 Aug; 26(8):683-8. PubMed ID: 11452174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 111In-pentetreotide scintigraphy in the post-thyroidectomy follow-up of patients with medullary thyroid carcinoma.
    Celentano L; Sullo P; Klain M; Lupoli G; Cascone E; Salvatore M
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):131-3. PubMed ID: 9002771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.
    Treglia G; Villani MF; Giordano A; Rufini V
    Endocrine; 2012 Dec; 42(3):535-45. PubMed ID: 22527889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values.
    Golubić AT; Pasini Nemir E; Žuvić M; Mutvar A; Kusačić Kuna S; Despot M; Samardžić T; Huić D
    Nucl Med Commun; 2017 Jul; 38(7):636-641. PubMed ID: 28562377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. THE COMBINED USE OF CALCITONIN DOUBLING TIME AND
    Yang JH; Camacho CP; Lindsey SC; Valente FOF; Andreoni DM; Yamaga LY; Wagner J; Biscolla RPM; Maciel RMB
    Endocr Pract; 2017 Aug; 23(8):942-948. PubMed ID: 28614009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings.
    Adams S; Baum RP; Hertel A; Schumm-Draeger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Sep; 25(9):1277-83. PubMed ID: 9724377
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.
    Giraudet AL; Vanel D; Leboulleux S; Aupérin A; Dromain C; Chami L; Ny Tovo N; Lumbroso J; Lassau N; Bonniaud G; Hartl D; Travagli JP; Baudin E; Schlumberger M
    J Clin Endocrinol Metab; 2007 Nov; 92(11):4185-90. PubMed ID: 17726071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid.
    Caobelli F; Chiaravalloti A; Evangelista L; Saladini G; Schillaci O; Vadrucci M; Scalorbi F; Donner D; Alongi P;
    Ann Nucl Med; 2018 Jan; 32(1):7-15. PubMed ID: 28986764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Technetium-99m-sestamibi scanning in recurrent medullary thyroid carcinoma.
    Learoyd DL; Roach PJ; Briggs GM; Delbridge LW; Wilmshurst EG; Robinson BG
    J Nucl Med; 1997 Feb; 38(2):227-30. PubMed ID: 9025742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study on the clinical relevance of
    Califano I; Pitoia F; Chirico R; De Salazar A; Bastianello MJ
    Endocrine; 2022 Jun; 77(1):143-150. PubMed ID: 35489000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.
    Adams S; Baum R; Rink T; Schumm-Dräger PM; Usadel KH; Hör G
    Eur J Nucl Med; 1998 Jan; 25(1):79-83. PubMed ID: 9396878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels.
    Ong SC; Schöder H; Patel SG; Tabangay-Lim IM; Doddamane I; Gönen M; Shaha AR; Tuttle RM; Shah JP; Larson SM
    J Nucl Med; 2007 Apr; 48(4):501-7. PubMed ID: 17401085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
    Hoegerle S; Altehoefer C; Ghanem N; Koehler G; Waller CF; Scheruebl H; Moser E; Nitzsche E
    Radiology; 2001 Aug; 220(2):373-80. PubMed ID: 11477239
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (18)F-DOPA PET/CT in the diagnosis and localization of persistent medullary thyroid carcinoma.
    Archier A; Heimburger C; Guerin C; Morange I; Palazzo FF; Henry JF; Schneegans O; Mundler O; Abdullah AE; Sebag F; Imperiale A; Taïeb D
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1027-33. PubMed ID: 26497699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.